Austind Kim News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Austind kim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Austind Kim Today - Breaking & Trending Today

Acadia Pharmaceuticals: New DAYBUE Drug Already Showing Signs Of Slowing (NASDAQ:ACAD)

Acadia Pharmaceuticals: New DAYBUE Drug Already Showing Signs Of Slowing (NASDAQ:ACAD)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Doug Williamson , Austind Kim , Mark Schneyer , Pharmaceuticals Inc , Head Of Research , Full Year , Clinical Studies , Acadia Clinical Studies , Executive Vice President , General Counsel , Acadia Insider Sales , Open Insider ,

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Sells $17,676.40 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Austin D. Kim sold 590 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $29.96, for a total transaction of $17,676.40. Following the transaction, the executive vice president now owns 46,901 shares of the […] ....

Austind Kim , Raymond James Financial Services Advisors Inc , Pharmaceuticals Daily , Metlife Investment Management , Acadia Pharmaceuticals Inc , Pharmaceuticals Inc , Pharmaceuticals Trading Down , Morgan Stanley , Hightower Advisors , Jpmorgan Chase Co , Get Free Report , Trading Down , James Financial Services Advisors , Tower Advisors , Life Investment Management , Canada Pension Plan Investment Board , Acadia Pharmaceuticals , Nasdaq Acad , Insider Trading , Nsider Trades ,

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $40.00 Price Target at Mizuho

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price hoisted by equities research analysts at Mizuho from $35.00 to $40.00 in a note issued to investors on Friday, MarketBeat.com reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price indicates a potential upside of 27.75% from the […] ....

Stephen Davis , Stifel Nicolaus , Austind Kim , Nemes Rush Group , Royal Bank , Acadia Pharmaceuticals , Pharmaceuticals Daily , Lazard Asset Management , Morgan Stanley , Cm Bidwell Associates Ltd , Cantor Fitzgerald , Pharmaceuticals Price Performance , Pharmaceuticals Inc , China Universal Asset Management Co , Get Free Report , Rush Group , Universal Asset Management , Asset Management , Nasdaq Acad , Boost Price Target ,